KING OF PRUSSIA, Pa., Dec. 11 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of PolyMedix Inc. (OTC Bulletin Board: PYMX) with a BUY rating and a $9.00 price target. PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. The Company's leading clinical development programs include the antibiotic PMX-30063 and the heparin antagonist PMX-60056.
Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides distribution, research and trade execution, primarily for institutional clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies.
Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report.
This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security.
Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. For these and other reasons, the investments discussed or recommended
SOURCE Emerging Growth Equities, Ltd.
Copyright©2008 PR Newswire.
All rights reserved